No Data
Wesheng Pharmaceutical-B (02561): Stabilization price action, end of stabilization period, and expiration of the over-allotment option.
Weisheng Pharmaceutical-B (02561) announced that the stabilization period related to the Global offering ended in April 2025...
Hong Kong stocks movement | Wei Sheng Pharmaceutical-B (02561) rose over 4% in early trading, core product Longpei Growth Hormone is expected to be approved in 2025.
Weisheng Pharmaceutical-B (02561) rose more than 4% in the morning session, and as of the time of writing, it has increased by 3.1%, priced at 54.8 Hong Kong dollars, with a transaction amount of 1.4565 million Hong Kong dollars.
VISEN PHARMA-B: FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024
The Hong Kong stock "first growth and development stock" Weisheng Pharmaceutical-B (02561) was officially listed, raising a total amount of over 0.1 billion US dollars, with rare support from both new and old Shareholders appearing together.
Weisheng Pharmaceutical will become the first Innovative Drugs company to be listed on the Hong Kong Stock Exchange in 2025 and will also become the "first stock of growth and development" in the Hong Kong stock market.
Express News | Shares of Visen Pharmaceuticals Set to Open at HK$68.80 Each in Hong Kong Debut Vs Offer Price HK$68.80 Apiece
Weisheng Pharmaceutical-B (02561) has a per share issue price of HKD 68.8, with the Hong Kong public offering receiving 72.64 times subscription.
Weisheng Pharmaceuticals-B (02561) announced the distribution results, with the company offering a total of 11.385 million shares globally, including a public offering in Hong Kong...
